These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25463408)

  • 1. Breast Imaging Reporting and Data System category 3 for magnetic resonance imaging.
    Lee KA
    Top Magn Reson Imaging; 2014 Dec; 23(6):337-44. PubMed ID: 25463408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BI-RADS 3 for magnetic resonance imaging.
    Comstock C; Sung JS
    Magn Reson Imaging Clin N Am; 2013 Aug; 21(3):561-70. PubMed ID: 23928245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency of Malignancy and Imaging Characteristics of Probably Benign Lesions Seen at Breast MRI.
    Grimm LJ; Anderson AL; Baker JA; Johnson KS; Walsh R; Yoon SC; Ghate SV
    AJR Am J Roentgenol; 2015 Aug; 205(2):442-7. PubMed ID: 26204298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of BI-RADS Assessment Category 4 Subdivisions for Screening Breast MRI.
    Strigel RM; Burnside ES; Elezaby M; Fowler AM; Kelcz F; Salkowski LR; DeMartini WB
    AJR Am J Roentgenol; 2017 Jun; 208(6):1392-1399. PubMed ID: 28792802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interobserver Variability Between Breast Imagers Using the Fifth Edition of the BI-RADS MRI Lexicon.
    Grimm LJ; Anderson AL; Baker JA; Johnson KS; Walsh R; Yoon SC; Ghate SV
    AJR Am J Roentgenol; 2015 May; 204(5):1120-4. PubMed ID: 25905951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Observer variability and applicability of BI-RADS terminology for breast MR imaging: invasive carcinomas as focal masses.
    Kim SJ; Morris EA; Liberman L; Ballon DJ; La Trenta LR; Hadar O; Abramson A; Dershaw DD
    AJR Am J Roentgenol; 2001 Sep; 177(3):551-7. PubMed ID: 11517046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of probably benign breast MRI lesions.
    Eby PR; DeMartini WB; Gutierrez RL; Saini MH; Peacock S; Lehman CD
    AJR Am J Roentgenol; 2009 Sep; 193(3):861-7. PubMed ID: 19696303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BI-RADS lesion characteristics predict likelihood of malignancy in breast MRI for masses but not for nonmasslike enhancement.
    Gutierrez RL; DeMartini WB; Eby PR; Kurland BF; Peacock S; Lehman CD
    AJR Am J Roentgenol; 2009 Oct; 193(4):994-1000. PubMed ID: 19770321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MR imaging in probably benign lesions (BI-RADS category 3) of the breast.
    Gökalp G; Topal U
    Eur J Radiol; 2006 Mar; 57(3):436-44. PubMed ID: 16316732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BI-RADS decoded: detailed guidance on potentially confusing issues.
    D'Orsi CJ; Newell MS
    Radiol Clin North Am; 2007 Sep; 45(5):751-63, v. PubMed ID: 17888766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probably benign breast MRI lesions: frequency, lesion type, and rate of malignancy.
    Lourenco AP; Chung MT; Mainiero MB
    J Magn Reson Imaging; 2014 Apr; 39(4):789-94. PubMed ID: 24108546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast imaging reporting and data system (BI-RADS) lexicon for breast MRI: interobserver variability in the description and assignment of BI-RADS category.
    El Khoury M; Lalonde L; David J; Labelle M; Mesurolle B; Trop I
    Eur J Radiol; 2015 Jan; 84(1):71-76. PubMed ID: 25454100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Stereotactic Mammotome breast biopsy: routine clinical experience and correlation with BI-RADS--classification and histopathology].
    Michel SC; Löw R; Singer G; Otto R; Hohl M; Kubik RA
    Praxis (Bern 1994); 2007 Sep; 96(39):1459-74. PubMed ID: 17966279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. False-positive findings at contrast-enhanced breast MRI: a BI-RADS descriptor study.
    Baltzer PA; Benndorf M; Dietzel M; Gajda M; Runnebaum IB; Kaiser WA
    AJR Am J Roentgenol; 2010 Jun; 194(6):1658-63. PubMed ID: 20489110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Background parenchymal enhancement on baseline screening breast MRI: impact on biopsy rate and short-interval follow-up.
    Hambly NM; Liberman L; Dershaw DD; Brennan S; Morris EA
    AJR Am J Roentgenol; 2011 Jan; 196(1):218-24. PubMed ID: 21178070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of the American College of Radiology BI-RADS guidelines by community radiologists: concordance of assessments and recommendations assigned to screening mammograms.
    Lehman C; Holt S; Peacock S; White E; Urban N
    AJR Am J Roentgenol; 2002 Jul; 179(1):15-20. PubMed ID: 12076896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revisiting Nonmass Enhancement in Breast MRI: Analysis of Outcomes and Follow-Up Using the Updated BI-RADS Atlas.
    Chikarmane SA; Michaels AY; Giess CS
    AJR Am J Roentgenol; 2017 Nov; 209(5):1178-1184. PubMed ID: 28834447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concordance of BI-RADS Assessments and Management Recommendations for Breast MRI in Community Practice.
    Lee AY; Ichikawa L; Lee JM; Lee CI; DeMartini WB; Joe BN; Wernli KJ; Sprague BL; Herschorn SD; Lehman CD
    AJR Am J Roentgenol; 2016 Jan; 206(1):211-6. PubMed ID: 26700354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BI-RADS update.
    Mercado CL
    Radiol Clin North Am; 2014 May; 52(3):481-7. PubMed ID: 24792650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the probably benign (BI-RADS category 3) assessment for masses on breast MRI: Is it transferable to general clinical practice?
    Price ER; Sickles EA; Yitta S; Brasic N; Yeh MJ; Allen IE; Joe BN
    Breast J; 2018 Mar; 24(2):109-114. PubMed ID: 28845605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.